News in Brief, February 2020

Trial Spotlight: Nabil Saba on Study EA3161 for HPV Positive Head and Neck Cancer
February 28, 2020
Social Media and Clinical Trials
February 28, 2020

News in Brief, February 2020

News in Brief


EA Trial Results in High-Impact Journals

The NCI-MATCH trial was recently featured in the Journal of the National Cancer Institute. The manuscript, The Molecular Analysis for Therapy Choice (NCI-MATCH) Trial: Lessons for Genomic Trial Design, highlights how NCI-MATCH is helping researchers and physicians navigate the complexities of molecular profiling for targeted therapies. View the article.

Results from trial E1609, led by Ahmad Tarhini, MD (Moffitt Cancer Center), were published in the Journal of Clinical Oncology in January. The study demonstrated an overall survival advantage with adjuvant ipilimumab at 3 mg/kg — but not at 10 mg/kg — compared to high-dose interferon alfa-2b in patients with resected high-risk cutaneous melanoma. This is the first time in melanoma adjuvant therapy that a study has shown a significant improvement in overall survival against an active control regimen. Learn more.

Edith Mitchell, MD Appointed to the President's Cancer Panel

In December, Edith Mitchell, MD, co-chair of ECOG-ACRIN’s Health Equity Committee, was appointed to the President’s Cancer Panel. Established in 1971, the panel is an independent advisory group that reports to the President on barriers to progress in reducing the cancer burden and develops recommendations. Learn more.







Introducing 'Considering Clinical Trials: A Blog About Cancer Treatment Options'

Together with the cancer Research Advocates Committee ECOG-ACRIN has launched a new blog featuring news, editorials, and perspectives by cancer research advocates. Updated quarterly, the blog highlights issues important patients and survivors, new and ongoing ECOG-ACRIN trials, and results from completed trials. View the blog, and please share it with your staff, outreach coordinators, and local advocacy groups.

Registration is Now Open for Spring 2020 Group Meeting

Register now for the ECOG-ACRIN Spring 2020 Group Meeting, taking place Wednesday, April 29 – Friday, May 1 at the Baltimore Marriott Waterfront in Baltimore, Maryland. Please note that this meeting marks a departure from the usual Thursday – Saturday schedule and takes place Wednesday – Friday.

After registering, you will be connected to the hotel reservation page. You will also receive a confirmation email with a link to book your hotel room in the ECOG-ACRIN block. The hotel reservation deadline is Wednesday, April 1, but our room block may sell out prior to that date.

For those planning further ahead, the Fall 2020 Group Meeting will take place Wednesday, October 21 – Friday, October 23 at the Marriott Harbor Beach Hotel in Fort Lauderdale, Florida.

Group Meeting Travel Funds Available for Clinical Research Associates

The ECOG-ACRIN CRA Core Committee has limited funds available to provide travel assistance to the Spring Group Meeting. Four candidates will be selected to receive a travel expense reimbursement award of up to $1,000. These funds are intended to facilitate attendance for CRAs with no other form of travel support. Data managers, clinical research associates or clinical research coordinators/nurses (who enter their own data) are eligible to apply. Only one candidate per institution will be supported.

Applications must be submitted no later than Friday, March 20. Apply now.

Deadline Approaching for Young Investigator Award Nominations, Paul Carbone, MD Fellowship Applications

Nominations for the 2020 Young Investigator Award, as well as applications for the 2020 Paul Carbone, MD Fellowship Award, must be submitted by Thursday, February 27, 2020.

The Young Investigator Award is a professional honor that recognizes scientific achievements made by investigators during the early years of their careers.

The Paul Carbone, MD Fellowship Award is a research grant that develops and promotes excellence in clinical trials, leading to improvements in cancer care

Leave a Reply

Your email address will not be published.